Document is current
Any future updates will be listed below
-
Authors
Mallardo, Domenico http://orcid.org/0000-0002-1081-5313
Fordellone, Mario http://orcid.org/0000-0003-0790-892X
White, Andrew
Ottaviano, Margaret http://orcid.org/0000-0001-9589-0808
Sparano, Francesca http://orcid.org/0000-0003-3348-6281
Bailey, Michael http://orcid.org/0000-0002-2727-4883
Facchini, Arianna Bianca http://orcid.org/0000-0001-7564-5100
Ong, Sufey
Maiolino, Piera http://orcid.org/0000-0002-8473-2254
Caracò, Corrado http://orcid.org/0000-0002-7828-079X
Church, Sarah
Cavalcanti, Ernesta http://orcid.org/0000-0001-6302-1579
Warren, Sarah
Budillon, Alfredo http://orcid.org/0000-0002-6330-6053
Cesano, Alessandra
Simeone, Ester http://orcid.org/0000-0003-2964-0434
Chiodini, Paolo http://orcid.org/0000-0003-0139-2264
Ascierto, Paolo Antonio http://orcid.org/0000-0002-8322-475X
- License Information
-
More Information
Article History
Received: 12 July 2023
Accepted: 5 August 2023
First Online: 8 September 2023
Declarations
:
: All subjects provided informed written consent prior to enrollment in the study. All procedures performed were in accordance with the 1964 Helsinki declaration and its later amendments. This study was approved by the Ethics Committee of Istituto Nazionale Tumori—IRCCS—Fondazione “G. Pascale”, Naples, Italy, protocol number 17/17 oss. All patients released informed consent to participate.
: All participants released consent to the publication of anonymous data.
: PAA has/had a consultant/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health. He also received research funding from Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi. AC received grant consultancies from BMS, Astrazeneca, Roche and MSD. He also received speaker’s fee from Astrazeneca, Novartis and Eisai.
